Our Pricing

Understanding Mounjaro: UK Prescription Weight Loss Treatment

Searching for mounjaro tablets uk online? It's important to clarify that Mounjaro (tirzepatide) is currently available in the UK exclusively as a pre-filled injection pen, not as oral tablets. At Cured Pharmacy, our UK-registered clinical team can assess your suitability for Mounjaro injections from £135.00 with transparent pricing and discreet delivery across the UK.

Is Mounjaro Available as Tablets in the UK?

Mounjaro is not currently licensed as a tablet formulation in the UK. The medication contains tirzepatide, a dual GIP/GLP-1 receptor agonist that is administered via subcutaneous injection using the KwikPen device [1]. This injectable delivery system ensures optimal bioavailability and consistent absorption, which is essential for the medication's efficacy.

Whilst oral semaglutide (Wegovy® tablets) has recently become available as a pre-order option in the UK, tirzepatide remains injection-only. The MHRA has licensed Mounjaro exclusively in its injectable form, with weekly subcutaneous administration being the approved route [2]. Any website claiming to sell Mounjaro tablets should be approached with extreme caution, as these would not be genuine UK-licensed products.

If you're specifically seeking an oral weight loss medication, alternatives like Orlistat (available from £135.00) or the newly available Wegovy® oral tablets may be more suitable. Your UK prescriber can discuss all licensed options during your free consultation.

How Mounjaro Injections Work for Weight Loss

Mounjaro contains tirzepatide, the first medication to target both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors simultaneously [1]. This dual mechanism distinguishes it from single-pathway treatments like Wegovy or Saxenda, which act solely on GLP-1 receptors.

The dual action works by slowing gastric emptying, reducing appetite, improving insulin sensitivity, and decreasing glucagon secretion. In the landmark SURMOUNT-1 trial, participants achieved an average weight reduction of up to 22.5% of their initial body weight over 72 weeks on the highest dose — significantly greater than comparator medications [3]. These results represent some of the most substantial weight loss outcomes observed in clinical trials for non-surgical interventions.

The medication is administered once weekly via a simple subcutaneous injection, typically into the abdomen, thigh, or upper arm. The KwikPen device is pre-filled and designed for ease of use, with most patients becoming confident with self-administration after their first injection.

Clinical Trial Evidence

The SURMOUNT clinical trial programme evaluated tirzepatide across diverse patient populations. SURMOUNT-1 enrolled adults with obesity or overweight with weight-related comorbidities, demonstrating dose-dependent weight loss ranging from 15% to 22.5% over 72 weeks [3]. SURMOUNT-2 specifically assessed patients with type 2 diabetes, showing similar efficacy alongside improved glycaemic control [4].

Importantly, these trials also measured cardiometabolic improvements beyond weight loss, including reductions in waist circumference, blood pressure, and inflammatory markers. Subject to prescriber assessment, Mounjaro may offer comprehensive metabolic benefits for eligible patients.

Mounjaro Dosing Schedule and Titration

Mounjaro follows a structured dose escalation protocol designed to minimise gastrointestinal side effects whilst optimising weight loss outcomes. All patients begin with a 2.5 mg once-weekly injection for the first four weeks [1]. This starter dose allows your body to adjust to the medication's effects on gastric emptying and appetite regulation.

After the initial month, your prescriber will typically increase the dose to 5 mg weekly, with further escalations every four weeks if tolerated. Available maintenance doses include 7.5 mg, 10 mg, 12.5 mg, and 15 mg, with the optimal dose determined by your individual response, tolerability, and weight loss progress [2]. Most patients reach their maintenance dose within 16 to 20 weeks of starting treatment.

It's essential to follow the prescribed titration schedule rather than increasing doses prematurely. Rapid escalation significantly increases the risk of nausea, vomiting, and other gastrointestinal effects. Your UK prescriber will monitor your progress through follow-up consultations and adjust your dose accordingly.

What to Expect During Dose Escalation

During the titration phase, you may notice gradual appetite suppression and modest weight loss even at lower doses. Some patients experience mild gastrointestinal symptoms during the first few days after each dose increase, which typically resolve within a week. Eating smaller portions, avoiding high-fat foods, and staying well-hydrated can help manage these temporary effects.

Your prescriber may pause dose escalation or maintain a lower dose if you experience persistent side effects or achieve satisfactory weight loss. There is no requirement to reach the maximum dose — the optimal dose is the one that provides effective weight management with tolerable side effects for your individual circumstances.

Common Side Effects and How to Manage Them

The most frequently reported side effects of Mounjaro are gastrointestinal, including nausea, diarrhoea, vomiting, constipation, and abdominal discomfort [1]. In clinical trials, these effects were most common during dose escalation and typically decreased in intensity over time. Approximately 10-20% of participants experienced nausea at some point during treatment, though severe cases leading to discontinuation were less common [3].

To minimise gastrointestinal symptoms, eat smaller, more frequent meals rather than large portions. Avoid foods high in fat or heavily spiced dishes, as these can exacerbate nausea. Stay well-hydrated, particularly if experiencing vomiting or diarrhoea. Many patients find that symptoms improve significantly after the first few weeks at each new dose level.

Less common but important side effects include injection site reactions (redness, itching, swelling), fatigue, and dizziness. Rare but serious adverse effects may include pancreatitis, gallbladder problems, and thyroid tumours (observed in animal studies). Contact your prescriber immediately if you experience severe abdominal pain, persistent vomiting, or signs of an allergic reaction.

Mounjaro vs Wegovy vs Saxenda: UK Treatment Comparison

All three medications are injectable GLP-1 receptor agonists licensed by the MHRA for weight management in the UK, but they differ in mechanism, dosing frequency, and clinical outcomes. Mounjaro (tirzepatide) uniquely targets both GIP and GLP-1 receptors, whilst Wegovy (semaglutide) and Saxenda (liraglutide) act solely on GLP-1 receptors [1][2].

Wegovy is administered once weekly at a maximum maintenance dose of 2.4 mg, with clinical trials showing average weight loss of approximately 15% over 68 weeks in the STEP-1 trial [5]. Saxenda requires daily injections at a maximum dose of 3 mg, with more modest weight loss outcomes of around 8% observed in the SCALE trials [6]. Mounjaro's dual mechanism has demonstrated superior weight loss compared to both alternatives in head-to-head studies.

Dosing convenience also differs: Mounjaro and Wegovy require only one injection per week, whilst Saxenda necessitates daily administration. Cost considerations, individual tolerability, and specific medical history all influence which medication your UK prescriber recommends. At Cured Pharmacy, we offer all three options with transparent pricing and can guide you towards the most suitable choice during your free consultation.

Choosing Between Injectable Options

Your prescriber will consider several factors when recommending a specific medication: your weight loss goals, previous treatment responses, medical conditions (particularly type 2 diabetes), injection frequency preference, and budget. Patients with type 2 diabetes may particularly benefit from Mounjaro's dual action, which provides superior glycaemic control alongside weight loss [4].

If you've previously tried Saxenda or Wegovy with suboptimal results or tolerability issues, Mounjaro may offer an alternative mechanism worth exploring. Conversely, if cost is a primary concern, starting with more affordable options and escalating if needed represents a reasonable approach, subject to prescriber approval.

Getting Mounjaro Through Cured Pharmacy

Mounjaro is a prescription-only medication in the UK, requiring clinical assessment by a UK-registered prescriber before dispensing. At Cured Pharmacy, the process begins with a free online consultation that takes under three minutes to complete. You'll answer questions about your medical history, current medications, weight management goals, and any contraindications.

Our UK clinical team, led by Superintendent Pharmacist Tarun Kumar (GPhC 2233073), reviews every consultation individually. If Mounjaro is deemed clinically appropriate for you, a prescription is issued and your medication is dispensed from our GPhC-registered pharmacy (9012511). We guarantee 100% discreet packaging and offer competitive delivery options across the UK.

Pricing is transparent from the outset — you'll see the exact cost before completing your consultation, with no hidden fees or surprise charges. Mounjaro starts from £135.00 at Cured Pharmacy, representing competitive UK pricing for genuine, licensed medication. Follow-up consultations are included to monitor your progress, adjust doses, and ensure ongoing safety throughout your treatment journey.

What You'll Need for Your Consultation

Before starting your consultation, have your current weight and height measurements ready, along with details of any existing medical conditions and medications you're taking. If you've previously used weight loss medications, note which ones and your response to them. This information helps your prescriber make an informed decision about your suitability for Mounjaro.

Be honest about your lifestyle, dietary habits, and weight loss history. Mounjaro works most effectively when combined with reduced-calorie diet and increased physical activity — your prescriber will discuss realistic expectations and the importance of comprehensive lifestyle modifications alongside medication.

Scientific References

1. Electronic Medicines Compendium. (2024). Mounjaro 2.5 mg solution for injection in pre-filled pen - Summary of Product Characteristics. Retrieved from https://www.medicines.org.uk/emc/product/14298
2. Medicines and Healthcare products Regulatory Agency. (2023). Mounjaro (tirzepatide): authorised for weight management in adults. Drug Safety Update, 17(2). Retrieved from https://www.gov.uk/drug-safety-update
3. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
4. Garvey, W. T., Frias, J. P., Jastreboff, A. M., et al. (2023). Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. The Lancet, 402(10402), 613–626. https://doi.org/10.1016/S0140-6736(23)01200-X
5. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
6. Pi-Sunyer, X., Astrup, A., Fujioka, K., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss outcomes depend on adherence to treatment, dietary modifications, and physical activity levels.